Mycosis Fungoides and Sézary Syndrome
Authors:
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 33 (1) , 103-120
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL PatientsScience Translational Medicine, 2012
- Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerJournal of Clinical Oncology, 2011
- Infectious agents in cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2011
- Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)Journal of the American Academy of Dermatology, 2010
- Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviorsBlood, 2010
- Skin-Resident T Cells: The Ups and Downs of On Site ImmunityJournal of Investigative Dermatology, 2010
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- Defining early mycosis fungoidesJournal of the American Academy of Dermatology, 2005
- Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patientsJournal of the American Academy of Dermatology, 2003
- Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results in twenty-nine patientsJournal of the American Academy of Dermatology, 1996